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Increased generation of platelet-derived microparticles
following percutaneous transluminal coronary angioplasty
Judy A. Craft and Neville A. Marsh
Platelet-derived microparticles that are produced during
platelet activation bind to traumatized endothelium. Such
endothelial injury occurs during percutaneous transluminal
coronary angioplasty. Approximately 20% of these patients
subsequently develop restenosis, although this is
improved by treatment with the anti-platelet glycoprotein
IIb/IIIa receptor drug abciximab. As platelet activation
occurs during angioplasty, it is likely that platelet-derived
microparticles may be produced and hence contribute to
restenosis. This study population consisted of 113
angioplasty patients, of whom 38 received abciximab.
Paired peripheral arterial blood samples were obtained
following heparinization and subsequent to all vessel
manipulation. Platelet-derived microparticles were
identified using an anti-CD61 (glycoprotein IIIa)
fluorescence-conjugated antibody and flow cytometry.
Baseline clinical characteristics between patient groups
were similar. The level of platelet-derived microparticles
increased significantly following angioplasty in the group
without abciximab (paired t test, P 0.019). However, there
was no significant change in the level of platelet-derived
microparticles following angioplasty in patients who
received abciximab, despite requiring more complex
angioplasty procedures. In this study, we have
demonstrated that the level of platelet-derived
microparticles increased during percutaneous transluminal
coronary angioplasty, with no such increase with
abciximab treatment. The increased platelet-derived
microparticles may adhere to traumatized endothelium,
contributing to re-occlusion of the arteries, but this
remains to be determined. Blood Coagul Fibrinolysis 14:
719–728 & 2003 Lippincott Williams & Wilkins.
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Introduction
Platelet-derived microparticles (PMPs) are produced by
a variety of in-vitro stimuli, such as thrombin, collagen
[1,2], high shear stress [3,4] and artificial surfaces [5],
while thromboxane A2 and adenosine diphosphate
(ADP) do not alter PMP numbers [6].
The PMP membrane is similar to that of platelets, as
PMPs produced from normal human blood contain
glycoprotein (GP) Ib [7,8] and the GPIIb/IIIa complex
[8,9], indicating potential roles in adhesion and aggrega-
tion. P-selectin is present on PMPs following C5b-9
assembly [10] or activation by thrombin with collagen
[2], suggesting that P-selectin is shed from the platelet
surface during PMP formation, although PMPs can be
generated without Æ-granule secretion [7,11]. PMPs
also contain activated factor IX [12], factor VIII [13],
activated factor X [14] and activated factor V [10],
suggesting that PMPs possess tenase and prothrombin-
ase activity and thus contribute to blood coagulation.
As the activated factor IX was more concentrated on
PMPs than platelets relative to surface area [12], PMPs
may in fact be proportionally more procoagulant than
platelets.
Elevated levels of PMPs occur in a number of cardio-
vascular disorders, including small and large vessel
cerebrovascular accidents [15], unstable angina [16],
and patients with a recent myocardial infarction [17]. In
addition, idiopathic thrombocytopaenia purpura pa-
tients with the highest levels of PMPs were asympto-
matic, indicating the PMP protective benefit from
bleeding [18].
Percutaneous transluminal coronary angioplasty
(PTCA) is a widely used treatment of coronary artery
disease. However, the balloon inflation during PTCA is
sufficient to cause endothelial damage [19], thus expos-
ing the subendothelial components including the base-
ment membrane and collagen. This can lead to platelet
activation and restenosis. Although adverse coronary
events occur in approximately 20% of patients [20,21],
the use of antiplatelet medication such as abciximab
(anti-platelet GPIIb/IIIa complex) decreases this to
16.5% [21].
It is possible that during PTCA the resultant platelet
activation also causes PMP production. This may have
clinical importance for PTCA patients, as it is known
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that PMPs are procoagulant and have roles in adhesion
and aggregation, and thus PMPs may contribute to
restenosis after PTCA. Accordingly, the present study
was designed to determine whether the levels of PMPs
were altered during PTCA, and to examine any influ-
ence of abciximab on this process.
Methods
Patient population
The study population consisted of 113 patients under-
going elective PTCA, and the patient characteristics
are presented in Table 1. The antiplatelet agent
abciximab (ReoPro) was administered to 38 of these
patients. Subjects were not randomized to abciximab or
placebo treatment in this observational study due to
the ethical implications of preventing high-risk patients
from receiving abciximab treatment. Therefore, abcix-
imab was administered in accordance with the standard
guidelines for administration (namely, high risk of
abrupt vessel closure). A bolus dose of heparin was
administered to all patients prior to PTCA, with non-
abciximab patients receiving 110 U/kg heparin and
abciximab patients receiving 100 U/kg heparin. The
standard abciximab dosing regime of 0.25 mg/kg bolus
and a 10 g/min 12 h infusion was used, with the bolus
dose being administered prior to completion of PTCA.
All patients were receiving ongoing aspirin treatment in
conjunction with clopidogrel used in the month follow-
ing PTCA. Relevant patient medical history was ob-
tained, while progress information was documented at
1 month  1 week, 6 months  2 weeks, and 12 months
 4 weeks after PTCA for incidence of angina, PTCA,
coronary artery bypass grafting (CABG) or death. Ex-
perience of angina was documented by means of a
qualitative questionnaire recording incidence of chest
pain. Informed consent was obtained from all partici-
pants, and research was performed with approval from
The Prince Charles Hospital and Queensland Univer-
sity of Technology human research ethics committees.
Blood collection and preparation
Paired peripheral arterial blood samples from the
PTCA sheath were collected into 0.105 mol/l sodium
citrate anticoagulant tubes. The first sample was ob-
tained following heparinization (baseline sample), while
the second sample was taken subsequent to all balloon
inflations and stent placement (post-PTCA sample),
and this sample contained abciximab when admin-
istered. In order to avoid a possible artifactual increase
in PMPs due to heparin, all blood samples in this study
were obtained following patient heparinization. Only
samples taken from the sheath during PTCA were
obtained and tested, as the higher shear forces of
sampling by venipuncture at other times would make
such samples incomparable with those obtained
through the wider lumen of the PTCA sheath. Whole
blood was diluted (1/10) in Dulbecco’s phosphate
buffer, and then added in equal quantities to undiluted
monoclonal antibodies and incubated in the dark for
3 min. A further dilution in 500 l Dulbecco’s phos-
phate buffer was followed by immediate flow cytome-
try. These minimal incubation times allowed flow
cytometry of samples at approximately 5 min ex vivo.
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Table 1 Comparison of patient characteristics between the patient groups without
abciximab and with abciximab
Characteristic
Without abciximab
(n ¼ 75)
With abciximab
(n ¼ 38) P value
Age (years) 62.9  1.14 61.0  1.96 NS
Male gender 62 (82.7%) 31 (81.6%) NS
Coronary risk factors:
Hypertension 46 (61.3%) 21 (55.3%) NS
Hyperlipidaemia 64 (85.3%) 27 (71.1%) NS
Diabetes NS
Type I (IDDM) 1 (1.3%) 0 (0.0%)
Type II (NIDDM) 5 (6.7%) 3 (7.9%)
Smoking NS
Never smoked 22 (29.3%) 12 (31.6%)
Quit at least 1 month prior 43 (57.3%) 22 (57.9%)
Smoking within 1 month 10 (13.3%) 4 (10.5%)
Previous myocardial infarction 32 (42.7%) 17 (44.7%) NS
Previous percutaneous transluminal
coronary angioplasty
18 (24.0%) 3 (7.90%) 0.043
Previous coronary artery bypass graft 12 (16.0%) 5 (13.2%) NS
Medications
Lipid lowers 47 (62.7%) 21 (55.3%) NS
-blockers 41 (54.7%) 25 (65.8%) NS
Ion channel modifiers 34 (45.3%) 20 (52.6%) NS
Peripheral vasodilators 34 (45.3%) 27 (71.1%) 0.010
Age is expressed as mean  standard error of mean. All other characteristics are expressed as number of
patients and percentage of the patient group. P values from chi-squared tests for age, diabetes and smoking,
and Fisher’s exact tests for other variables. IDDM, insulin-dependent diabetes mellitus; NIDDM, non-insulin-
dependent diabetes mellitus; ns, not significant.
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As a positive control for the PMP levels, a sample of
plasma was obtained by centrifugation at 3000 3 g for
10 min. This was then subjected to a twice freeze–
thaw cycle, and diluted and stained as for the normal
whole blood. The purpose of this procedure was to
produce PMPs in significant numbers by freezing and
thawing, thus providing biological material with which
to validate the flow cytometry analysis of PMPs. A
positive control used for the PMP levels and the
expression of CD62P and PAC1 was by addition of
100 mol/l ADP (Helena Laboratories, Beaumont,
Texas, USA) during antibody incubation.
Monoclonal antibodies
Peridinin chlorophyll protein-conjugated anti-CD61,
fluorescein isothiocyanate-conjugated anti-PAC1, and
phycoerythrin-conjugated anti-CD62P were purchased
from Becton Dickinson (San Jose, California, USA).
These were used to identify the platelet membrane
GPIIIa (anti-CD61), the platelet membrane GPIIb/IIIa
complex on activated platelets (anti-PAC1), and the
membrane protein P selectin (GMP-140, PADGEM)
that is released upon Æ-granule secretion (anti-CD62P).
Anti-CD61 was used to identify PMPs and platelets as
it is known that PMPs express GPIIIa [7], and was
therefore used in every tube. For measurement of
CD62P and PAC1, triple staining in combination with
CD61 was used.
To ensure that abciximab did not interfere with the
binding of CD61, in-vitro testing was performed using
12 of the blood samples from the PTCA patients
consented to participate in this study. Heparinized
blood samples were obtained and paired aliquots were
treated simultaneously with or without abciximab
added in vitro (at the same dose normally administered
in vivo), followed by incubation with CD61. Samples
were otherwise treated in accordance with other sam-
ples in this study. There was no significant difference
in the level of PMPs between the CD61 tubes and the
CD61 with abciximab tubes (mean  standard error of
mean: 4.86  0.48, CD61 only; 4.47  0.49, CD61 with
abciximab; paired t test, P ¼ not significant). This
indicated that abciximab did not limit the binding of
CD61 to the PMPs.
Flow cytometry
Prepared blood was tested on a FACScan flow cyt-
ometer (Becton Dickinson), which was calibrated daily
using CaliBRITE three-colour beads and FACSComp
software (version 4.0, # 1995–97 Becton Dickinson).
Data acquisition and analysis was performed with
CELLQuest software (version 3.1, # 1994–97 Becton
Dickinson). The flow cytometer was set with the side
scatter (SSC) and fluorescence voltages on a logarithmic
(log) scale, and data acquired using a side scatter
threshold on a dot plot of CD61-log against SSC-log. A
region (R1) was set to acquire all data except that
which was CD61-negative with a high SSC profile
(leukocytes), with files containing 10 000 events. Analy-
sis was performed using a histogram of CD61-log
against counts to set a gate for the CD61-positive
events. These events were collected into a CD61-log
against SSC-log dot plot, where a region was set around
the PMP population (R2), and platelets (R3) were also
distinguished (Fig. 1). PMPs were identified as those
particles smaller than the unstimulated platelets that
were CD61-positive. The amount of PMPs was ex-
pressed as a percentage of all CD61-positive events
(PMP%). For other indicators of platelet activation, dot
plots of PAC1-log and CD62P-log against CD61-log
were used (Fig. 2), and PAC1 and CD62P expressed as
a percentage of all CD61-positive events.
Statistical analysis
Statistical analysis of patient baseline clinical character-
istics between the two groups was performed using
Fisher’s exact tests for gender, hypertension, hyperlipi-
daemia, medications, prior myocardial infarction, prior
PTCA and previous CABG, while chi-squared testing
was used for age, diabetes and smoking. Characteristics
of the PTCA procedure were compared between the
two patient groups, with arterial approach, number of
arteries treated, rotablation and occlusion aspiration
compared by chi-squared testing, while the number of
stents, number of inflations, the maximum inflation
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Fig. 1
Representative flow cytometry acquisition and analysis dot plot. R1
was set to acquire all data except that which was CD61-negative with
high side scatter profile. R2 was set around the platelet-derived
microparticles, and R3 was set around the platelets. The dot plot is
taken from one patient; the baseline sample is without abciximab
treatment.
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pressure and time, as well as total procedure time were
compared using analysis of variance.
The PMPs were analysed using one-tailed paired t
tests, and the results of these tests were confirmed
using regression and observing the significance of the
constant. The PAC1 and CD62P expression were also
compared using one-tailed paired t tests, as were results
of the frozen-thawed plasma and ADP in-vitro studies.
The paired t tests were calculated using Microsoft
Excel software (version 2000 # 1985–99 Microsoft),
while all other statistical analysis was made using
Datadesk software (version 6.0.1; Datadesk, Ithaca,
New York, USA).
Results
Patient clinical characteristics
A total of 75 patients without abciximab and 38 patients
with abciximab treatment were studied, with most
clinical characteristics being similar in both groups
(Table 1). More patients had previously undergone
PTCA in the group without abciximab than in the
group receiving abciximab (24.0 and 7.9%, respec-
tively), although a Fisher’s exact test demonstrated that
this difference was only marginally significant (P ¼
0.043). Both patient groups also had similar treatment
with lipid lowers, -blockers and ion channel modifiers,
although significantly more patients were being treated
with peripheral vasodilators in the abciximab group
(Fisher’s exact test, P ¼ 0.010).
Details of the PTCA procedure characteristics are
presented in Table 2. Patients who received abciximab
had significantly more complex PTCA procedures, as
they needed treatment of more coronary arteries (P ¼
0.011) and required more stents (P ¼ 0.039), with 27%
of patients without abciximab compared with 39% of
abciximab patients having multiple stents. Also, these
patients required significantly higher inflation pressures
(P ¼ 0.022) and maximum inflation times (P , 0.0001)
than those who did not receive the drug. The total
PTCA procedure time was longer for the abciximab
patients, although this did not reach statistical signifi-
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Fig. 2
Acquisition dot plots of (a), (c) PAC1-log and (b), (d) CD62P-log against CD61-log. (a) and (b) unstimulated samples, (c) and (d) same samples
after addition of in-vitro adenosine diphosphate. Dot plots are taken from one patient; the baseline sample is without abciximab treatment.
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cance (P ¼ 0.051). These differences prevented direct
statistical comparisons between patient groups.
In the PTCA follow-up period, angina was reported in
approximately 29–39% of patients at all time points
(Table 3). Small numbers of patients required further
PTCA in both patient groups (5.3% without abciximab
and 7.9% with abciximab), while none of the patients
receiving abciximab during their PTCA required
CABG. Of those not treated with abciximab, five
patients required subsequent revascularization as fol-
lows: patient 1 required PTCA within 6 months to a
native artery; patient 2 had PTCA to instent restenosis
of the right coronary artery at both 6 and 12 months;
patient 3 required a single CABG to instent restenosis
of the left anterior descending artery within 6 months,
with the graft site then treated by PTCA within
12 months; patient 4 required a triple CABG within
6 months to treat severe instent restenosis of the left
circumflex artery; and patient 5 had widespread arterial
occlusions requiring a sextuple CABG within 6 months.
The three patients treated with abciximab during their
PTCA who required subsequent PTCA included one at
6 months to the site of the original PTCA, and indivi-
duals at both 6 and 12 months who had different
arteries treated. The only incidence of death was in the
abciximab group. This patient received chemotherapy
on the day prior to death, and then deterioration
commenced with chest pain and shortness of breath,
leading into electromechanical dissociation, and death
at termination of mechanical ventilation. A total of 10
patients were not contactable at 1 month, which in-
creased to 19 patients uncontactable by 1 year.
PMP positive control using a twice freeze–thaw cycle
As a positive control to validate the flow cytometric
analysis of PMPs, corresponding samples of plasma
were subject to a twice freeze–thaw cycle to induce
PMP production. The frozen–thawed plasma contained
significantly more PMPs than the fresh whole blood,
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Table 2 Percutaneous transluminal coronary angioplasty procedure characteristics
Characteristic
Without abciximab
(n ¼ 75)
With abciximab
(n ¼ 38) P value
Arterial approach NS
Femoral artery 65 (86.7%) 34 (89.5%)
Radial artery 10 (13.3%) 3 (7.9%)
Brachial artery 0 (0.0%) 1 (1.3%)
Number of coronary arteries treated 0.0107
1 63 (84.0%) 23 (60.5%)
2 11 (14.7%) 15 (38.5%)
3 1 (1.3%) 0 (0.0%)
Number of stents used 0.0388
0 7 (9.3%) 5 (13.2%)
1 48 (64.0%) 18 (47.4%)
2 15 (20.0%) 6 (15.8%)
3 4 (5.3%) 4 (10.5%)
4 1 (1.3%) 4 (10.5%)
5 0 (0.0%) 1 (2.6%)
Rotablation 2 (2.7%) 1 (2.6%) NS
Occlusion aspiration 1 (1.3%) 0 (0.0%) NS
Number of inflations 4.89  0.36 6.19  0.71 NS
Maximum inflation time (s) 47.76  1.87 74.30  5.78 , 0.0001
Maximum inflation pressure (atm) 14.99  0.45 16.71  0.55 0.0219
Total procedure time (min) 38.38  2.31 48.19  4.87 0.0515
The arterial approach, number of coronary arteries treated, number of stents used, rotablation and occlusion
aspiration are expressed as the number of patients and percentage of the patient group, while other
characteristics are expressed as the mean  standard error of mean. The total procedure time was measured
from administration of heparin to withdrawal of the guidewire. P values are from chi-square tests for arterial
approach, number of arteries treated, rotablation and occlusion aspiration, and from analysis of variance tests
for other variables.
Table 3 Patient outcomes following percutaneous transluminal coronary angioplasty (PTCA)
Without abciximab (n ¼ 75) With abciximab (n ¼ 38)
Time of patient contact Angina PTCA CABG Death Angina PTCA CABG Death
1 month  1 week 23 (30.7%) 0 (0.0%) 1 (1.3%) 0 (0.0%) 14 (36.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
6 months  2 weeks 28 (37.3%) 1 (1.3%) 3 (4.0%) 0 (0.0%) 15 (39.5%) 2 (5.3%) 0 (0.0%) 0 (0.0%)
12 months  4 weeks 22 (29.3%) 3 (4.0%) 0 (0.0%) 0 (0.0%) 12 (31.6%) 1 (2.6%) 0 (0.0%) 1 (2.6%)
Patients were contacted up to 1 year following their PTCA for incidence of angina, PTCA, coronary artery bypass graft (CABG) or death. Results are expressed as the
number of patients and the percentage of the patient group.
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regardless of treatment with abciximab (Table 4).
There were significant increases of approximately 60–
64% in the baseline samples in both patient groups
(P , 0.001 without abciximab, P ¼ 0.030 with abcixi-
mab), and significant increases of approximately 105–
148% in the post-PTCA samples in both patient groups
(P , 0.001 for both groups).
Positive control using in-vitro ADP
The addition of in-vitro ADP affected the proportion of
CD61-positive PMPs. In both patient groups, the
percentage of PMPs was decreased in the presence of
ADP (Table 5). For non-abciximab patients, PMPs
decreased by approximately 25% in the baseline sample
and by approximately 20% in the post-PTCA sample
(P , 0.001 for both). In the abciximab patient group,
decreases of approximately 28% were also found in
the baseline sample, and in the post-PTCA sample a
decrease of approximately 44% occurred (P , 0.001).
The use of ADP produced significant increases in
expression of PAC1 in both the non-abciximab-treated
and abciximab-treated groups (Table 6). Substantial
increases of approximately five-fold were found in both
the baseline and post-PTCA sample for non-abciximab
patients (P , 0.001 for both groups). A significant in-
crease of approximately six-fold also occurred with
exogenous ADP in the abciximab-treated patients in
the baseline sample (P , 0.001). However, the ADP-
induced increase following administration of abciximab
during PTCA appeared to be limited with only a two-
fold increase (P ¼ 0.029).
In vitro ADP also significantly increased the expression
of CD62P in both patient groups (Table 6). In non-
abciximab patients, there were approximately seven-
fold to nine-fold increases in CD62P expression, with
the baseline and post-PTCA samples (P , 0.001 for
both). Similarly, for patients treated with abciximab,
increases were in the range of approximately 10-fold to
12-fold, for the baseline and post-PTCA samples
(P , 0.001 for both). It is interesting to note that the
apparent limitation of abciximab on ADP-induced
PAC1 expression (described earlier) was not evident for
the ADP-induced CD62P expression.
Total PAC1 and CD62P expression following PTCA
A slight non-significant decrease of 3.3% occurred in
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Table 4 Increased platelet-derived microparticles (PMPs) in frozen–thawed plasma
compared with fresh whole blood from percutaneous transluminal coronary angioplasty
(PTCA) patients
PMPs (% of CD61-positive events)
Baseline Post-PTCA
Patient group Fresh whole blood
Frozen–thawed
plasma Fresh whole blood
Frozen–thawed
plasma
Without abciximab 3.70  0.29 5.92  0.56 4.05  0.24 8.32  0.67
(n ¼ 75) (P , 0.001) (P , 0.001)
With abciximab 3.74  0.42 6.12  1.24 3.96  0.57 9.82  1.66
(n ¼ 38) (P ¼ 0.030) (P , 0.001)
Frozen–thawed plasma samples were incubated with anti-CD61-peridinin chlorophyll protein antibody and
tested by flow cytometry in the same manner as the samples tested at the time of PTCA. Values are
expressed as the mean  standard error of mean. P values are from a paired t test comparing the frozen–
thawed sample with the corresponding unfrozen whole blood sample.
Table 5 The effect of in-vitro adenosine diphosphate (ADP) on platelet-derived
microparticles (PMPs) in whole blood samples from percutaneous transluminal coronary
angioplasty (PTCA) patients
PMPs (% of CD61-positive events)
Baseline Post-PTCA
Patient group Without ADP With ADP Without ADP With ADP
Without abciximab 4.23  0.21 3.21  0.18 3.99  0.22 3.17  0.25
(n ¼ 75) (P , 0.001) (P , 0.001)
With abciximab 4.04  0.42 2.90  0.34 4.41  0.72 2.48  0.24
(n ¼ 38) (P , 0.001) (P , 0.001)
Whole blood samples were prepared with and without the addition of 100 mol/l ADP in vitro. Values are
expressed as the mean  standard error of the mean. P values are from a paired t test comparing samples
with and without the addition of ADP in vitro.
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total expression of PAC1 after PTCA in non-abciximab
patients (Table 7). However, there was a significant
decrease of 17.2% in PAC1 expression in patients
treated with abciximab (P ¼ 0.011). There was no
significant change in the total expression of CD62P in
all of the CD61-positive events from baseline to post-
PTCA, regardless of treatment with abciximab. Only a
slight increase of 2.5% occurred in non-abciximab pa-
tients and of 5.4% in abciximab patients.
Increase in PMPs following PTCA
There was a significant increase of 10.4% (P ¼ 0.019) in
the PMPs following PTCA in the patient group without
abciximab (Table 7). Although the numerical increase
is modest, results were confirmed by non-robust regres-
sion analysis, which demonstrated significance of the
constant (P , 0.01). In contrast, the PMPs in patients
who received abciximab did not show a significant
change, with an increase of only 4%.
Discussion
In this study we have examined the level of PMPs in
113 PTCA patients, of whom 38 received abciximab.
The patient groups were similar in baseline character-
istics such as age and coronary risk factors, although
significantly more patients not receiving abciximab had
previous PTCA therapy. This difference prevented
direct statistical comparisons between groups, and thus
parameters were compared before and after PTCA in
the same groups. The decision to treat with abciximab
is based on severity of cardiovascular disease, and
clearly those patients with more involved PTCA treat-
ment were ultimately treated with abciximab. A combi-
nation of factors including number of stents and more
vigorous inflations place this group of patients at higher
risk of restenosis, thus requiring the abciximab protec-
tion to limit platelet aggregation. Within the year
following PTCA, angina was relatively consistent be-
tween groups, with a tendency to decreased reporting
of angina by 1 year, although this effect may be partly
due to the inability to retain patient contact. While a
total of eight incidents of revascularization were re-
quired in the year following PTCA in patients not
treated with abciximab, five of these (6.7% of the
patient group) were due to direct restenosis. Of the
three incidents of revascularization needed for abcixi-
mab-treated patients, only one (2.6% of patient group)
was due to direct restenosis. It is interesting to note
that all of those requiring revascularization from the
abciximab group could be treated by PTCA rather than
CABG, indicating that the occlusions were of a lesser
severity and demonstrating the ability of abciximab to
limit subsequent restenosis.
As freeze–thaw cycles increase PMP production
[22,23], this technique was employed to generate high-
er PMP numbers and thus verify the measurement of
PMPs by flow cytometry. There was a significant
increase in PMPs when plasma was subjected to a twice
freeze–thaw cycle for all samples (regardless of abcix-
imab treatment), demonstrating appropriate PMP meas-
urement techniques. In the post-PTCA samples, the
twice freeze–thaw resulted in a much greater PMP
increase, which may be a reflection of the prothrombo-
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Table 6 The effect of in-vitro adenosine diphosphate (ADP) on PAC1 and CD62P in whole blood samples from percutaneous transluminal
coronary angioplasty (PTCA) patients
PAC1 (% of CD61-positive events) CD62P (% of CD61-positive events)
Baseline Post-PTCA Baseline Post-PTCA
Patient group Without ADP With ADP Without ADP With ADP Without ADP With ADP Without ADP With ADP
Without abciximab (n ¼ 75) 4.89  0.69 24.37  1.59
(P , 0.001)
4.73  0.49 23.37  1.89
(P , 0.001)
3.99  0.69 36.44  2.40
(P , 0.001)
4.09  0.80 36.56  2.65
(P , 0.001)
With abciximab (n ¼ 38) 3.73  0.27 22.17  2.83
(P , 0.001)
3.09  0.25 6.50  1.76
(P ¼ 0.029)
2.76  0.21 34.57  3.84
(P , 0.001)
2.91  0.48 30.64  3.87
(P , 0.001)
Whole blood samples were incubated with anti-CD61-peridinin chlorophyll protein, anti-PAC1-fluorescein isothiocyanate and phycoerythrin-conjugated anti-CD62P,
prepared with or without the addition of in-vitro ADP, and tested by flow cytometry. Values are expressed as the mean  standard error of mean. P values are from a
paired t test comparing with and without ADP.
Table 7 The effect of percutaneous transluminal coronary angioplasty (PTCA) on the number of platelet-derived microparticles (PMPs)
and expression of CD62P and PAC1 in whole blood samples
PMPs (% of CD61-positive events) PAC1 (% of all events) CD62P (% of all events)
Patient group Baseline Post-PTCA Baseline Post-PTCA Baseline Post-PTCA
Without abciximab (n ¼ 75) 3.75  0.25 4.14  0.22 (P ¼ 0.019) 4.89  0.69 4.73  0.49 (P ¼ NS) 3.99  0.69 4.09  0.80 (P ¼ NS)
With abciximab (n ¼ 38) 3.91  0.44 4.29  0.63 (P ¼ NS) 3.73  0.28 3.09  0.24 (P ¼ 0.011) 2.76  0.21 2.91  0.48 (P ¼ NS)
Whole blood samples were incubated with anti-CD61-peridinin chlorophyll protein antibody for the PMP results, or incubated with anti-CD61-peridinin chlorophyll
protein, anti-PAC1-fluorescein isothiocyanate and phycoerythrin-conjugated anti-CD62P for the PAC1 and CD62P results, and tested by flow cytometry. Values are
expressed as the mean  standard error of mean. P values are from a paired t test comparing baseline with post-PTCA. NS, not significant.
Increased platelet microparticles with PTCA Craft and Marsh 725
tic state induced by PTCA. While there was a 105%
increase PMPs in non-abciximab patients, an even
greater 148% increase occurred in abciximab patients.
Therefore, abciximab treatment has not limited the
ability of platelets to produce PMPs by freeze–thaw
cycles, and indicates that the GPIIb/IIIa site is not
essential for PMP production under these conditions.
This is supported by studies indicating that PMPs can
be produced either by GPIIb/IIIa-dependent or GPIIb/
IIIa-independent mechanisms [24,25].
These results demonstrate that the increase induced by
the freeze–thaw method is not merely a non-specific
response, as the increase ranged from 60 to 148%, with
higher increases seen in the post-PTCA samples.
Although comparisons were made between the fresh
whole blood and frozen–thawed plasma samples, these
results cannot be explained by a haematocrit effect as
the PMPs are measured by expression of CD61, which
is not affected by presence of other non-CD61-positive
cells such as erythrocytes. The increase in PMPs may
have been caused by increased budding, or by in-
creased platelet lysis, although this was not addressed
in this study. It is also possible that the larger PMPs
may be releasing smaller sized PMPs, as a variety of
PMP sizes have been reported and PMPs appear to be
heterogeneous [26]. Therefore, it may be possible that
PMPs actually vesiculate into smaller PMP fragments
under certain conditions, producing PMPs of a variety
of sizes.
There was a significant decrease in PMPs at all times
with the in-vitro addition of ADP. As ADP causes
platelet adhesion, it is probable that platelets and
PMPs have adhered to the flow cytometry tubes, thus
preventing them from being sampled and measured. It
is also probable that ADP may cause PMP aggregation
into larger particles, and thus they would no longer be
detected and counted in the PMP analysis region. It
has previously been demonstrated that ADP did not
cause an increase in PMPs [6]. It is interesting to note
that decreases of 20–28% were observed in most
samples, with a large decrease of 44% in the post-
PTCA sample when abciximab was used. Thus, the
largest decrease in PMPs with in-vitro ADP was ob-
served in the presence of abciximab. It is expected that
blood from post-PTCA samples in patients from the
abciximab group would be most prothrombotic due to
the complexity of their PTCA. Therefore, it is possible
that the addition of ADP to these blood samples caused
extensive adhesion and/or aggregation via a mechanism
not dependent on the GPIIb/IIIa complex, as it is
known that the GPIIb/IIIa complex is not essential for
vesiculation under particular conditions [24,25].
There were significant increases in PAC1 expression in
the presence of in-vitro ADP. However, the increase in
PAC1 expression was limited in the presence of
abciximab, as seen in the post-PTCA sample. As
abciximab blocks the GPIIb/IIIa site, it is probable that
it would limit the PAC1 binding. There was also a
significant increase in CD62P with ADP, with no
limitation of abciximab. As abciximab interacts with the
GPIIb/IIIa complex, it would not be expected to alter
the P-selectin expression. Together, these results in-
dicate that in-vitro ADP has resulted in platelet activa-
tion.
The expression of PAC1 did not alter significantly in
patients without abciximab treatment from baseline to
post-PTCA in this study. However, there was a signifi-
cant decrease in the level of PAC1 in abciximab
patients following PTCA, as abciximab is an antagonist
at the GPIIb/IIIa receptor and thus would limit PAC1
binding. In this study, peripheral arterial samples were
obtained, although within the coronary sinus a signifi-
cant increase in PAC1 expression has occurred follow-
ing PTCA [27], but there was no significant change in
PAC1 in peripheral venous blood [28]. In our study,
there was no significant change in CD62P following
PTCA regardless of abciximab use. Similar results with
no significant change in P-selectin have been obtained
in other work [27–29], and this is supported by in-vitro
work showing that Æ-degranulation may not be directly
related to PMP formation [30].
In the present study, we have clearly demonstrated that
the level of CD61-positive PMPs increased significantly
during PTCA in the group of 75 patients who were not
treated with abciximab. It is expected that factors
including the physical trauma due to balloon rupture of
the plaque, and exposed surfaces provided by suben-
dothelial structures and stents have contributed to the
prothrombotic state. This may possibly be related to
the increase in PMP formation. It is possible that
microparticles from other sources such as endothelial
cells were also altered with PTCA, although this was
not determined in the present study. This trend
towards increased PMPs has been noted in earlier
studies, but low sample sizes prevented statistical
significance being attained [27,29]. Our work demon-
strates a significant increase in PMPs that is supported
by statistical analysis (P ¼ 0.019). While we have exam-
ined peripheral arterial blood, recently published work
has also demonstrated a significant increase in PMPs in
peripheral venous blood following PTCA [28]. Our
results taken together with these results [28] conclu-
sively demonstrate that there is an increase in the
levels of PMPs with PTCA, as detected in both arterial
and venous blood samples.
It is possible that the increase in PMPs that we have
reported may be involved in restenosis after PTCA,
although our sample size limits significant incidence of
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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restenosis events. It is probable that the PMPs may
adhere to the traumatized site because, in an animal
model of arterial endothelial injury, labelled PMPs
were infused and there was a significantly higher in-
crease in PMP adhesion at the injured site compared
with at an uninjured site [31]. This significant PMP
adhesion could initiate thrombus formation and lead to
future ischaemic events. In earlier research, patients
with activated coagulation and fibrinolysis who died
due to acute myocardial infarction had fresh thrombi in
their coronary arteries. Further examination demon-
strated that those patients who died had the highest
levels of PMP-bound GPIIbÆ in blood samples taken
prior to death [32], which may have accelerated throm-
bi formation in the coronary vessels and contributed to
the adverse patient outcomes. These studies demon-
strate the possibility for PMPs to be involved in
adhesion and aggregation, and potentially contribute to
restenosis after PTCA.
In our study, the group of 38 patients treated with
abciximab did not have a significant alteration in the
level of PMPs. Therefore, it appears that the GPIIb/
IIIa complex may be essential in PMP vesiculation
during PTCA, as blocking this receptor with abciximab
has prevented platelet vesiculation. Blockage of the
GPIIb/IIIa Arg-Gly-Asp-Ser (RGDS) amino acid se-
quence has prevented PMP vesiculation [11], with the
common Arg-Gly-Asp (RGD) site being blocked by
abciximab in the present study. This clearly demon-
strates the effectiveness of abciximab because, despite
the more complex PTCA procedure, the level of PMPs
did not significantly alter. However, as patients with
Glanzmann’s thrombasthenia [24] and those with the
GPIIb/IIIa site blocked with other antibodies [25] are
still able to produce PMPs, it is probable that, under
certain conditions, an additional mechanism(s) of plate-
let vesiculation is involved.
Study limitations
As this study was non-randomized, it is acknowledged
that there may be other important differences between
the abciximab-treated and non-treated groups. Further-
more, the significant differences in the PTCA charac-
teristics discussed contribute to differences in the study
populations, while the differences in sample sizes have
prevented direct comparisons between groups. Addi-
tional studies on abciximab-treated and non-abciximab-
treated patients are needed to confirm the PMP
changes during PTCA.
In conclusion, we have demonstrated that PTCA
results in an increase in PMPs in peripheral arterial
blood, a phenomenon that was prevented with the use
of abciximab. As PMPs appear to be involved in
adhesion, aggregation and blood coagulation, it is prob-
able that these PMPs may contribute to restenosis
events following PTCA, although the significance of
this remains undetermined.
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